{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalEntity"
  ],
  "@id": "dvt-007-anticoagulation",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T02:40:00.000Z",
    "contributors": [
      "copilot-agent",
      "vascular-surgery-knowledge-base"
    ],
    "confidence": 0.98,
    "status": "enhanced",
    "last_updated": "2026-01-05T02:40:00.000Z",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/deep-vein-thrombosis",
    "type": "treatment",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "007",
    "keywords": [
      "DVT anticoagulation",
      "DOAC",
      "warfarin",
      "LMWH",
      "VTE treatment"
    ],
    "medical_specialty": "vascular_surgery"
  },
  "content": {
    "statement": "dvt-007-anticoagulation is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Deep-Vein-Thrombosis that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding dvt-007-anticoagulation helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of dvt-007-anticoagulation include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of dvt-007-anticoagulation."
    },
    "anticoagulant_options": {
      "doacs": {
        "rivaroxaban": {
          "dose": "15mg BID x 21 days, then 20mg daily",
          "advantages": "No lead-in required",
          "renal": "Avoid if CrCl <30"
        },
        "apixaban": {
          "dose": "10mg BID x 7 days, then 5mg BID",
          "advantages": "Safest bleeding profile",
          "renal": "Avoid if CrCl <25"
        },
        "edoxaban": {
          "dose": "60mg daily after 5-10 days LMWH lead-in",
          "renal": "30mg if CrCl 30-50"
        },
        "dabigatran": {
          "dose": "150mg BID after 5-10 days parenteral lead-in",
          "advantages": "Idarucizumab reversal available"
        }
      },
      "lmwh": {
        "enoxaparin": {
          "dose": "1mg/kg BID or 1.5mg/kg daily",
          "monitoring": "Anti-Xa levels if renal impairment, obesity, pregnancy"
        },
        "indications": "Cancer-associated VTE (preferred), pregnancy, severe renal failure with close monitoring"
      },
      "warfarin": {
        "dose": "Target INR 2-3",
        "indications": "Antiphospholipid syndrome, severe renal failure, patient preference",
        "bridging": "Requires parenteral anticoagulation until INR therapeutic for \u22652 days"
      }
    }
  },
  "clinical_features": {
    "duration": {
      "provoked_transient_risk": {
        "examples": "Surgery, immobilization, hospitalization",
        "duration": "3 months"
      },
      "unprovoked": {
        "examples": "No identifiable risk factor",
        "duration": "Extended (indefinite), reassess annually"
      },
      "recurrent_vte": {
        "duration": "Extended (indefinite)"
      },
      "cancer_associated": {
        "duration": "As long as cancer active, reassess periodically"
      }
    },
    "special_populations": {
      "cancer": "LMWH or DOACs (edoxaban, rivaroxaban) preferred over warfarin",
      "pregnancy": "LMWH only - DOACs and warfarin contraindicated",
      "antiphospholipid": "Warfarin preferred - DOACs have higher thrombosis risk",
      "renal_failure": "Warfarin or dose-adjusted LMWH; avoid DOACs if severe CKD",
      "obesity": "Consider anti-Xa levels for LMWH; DOAC efficacy uncertain if >120kg or BMI >40"
    },
    "reversal_agents": {
      "warfarin": [
        "Vitamin K (slow)",
        "4-factor PCC (immediate)",
        "FFP"
      ],
      "dabigatran": [
        "Idarucizumab (Praxbind)"
      ],
      "xa_inhibitors": [
        "Andexanet alfa (Andexxa)",
        "4-factor PCC (off-label)"
      ]
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "DVT Anticoagulation"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "VTE Treatment"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "Anticoagulant therapy to prevent thrombus extension, embolization, and recurrence in deep vein thrombosis"
    },
    "notation": "dvt-007-anticoagulation"
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "urn:wskg:medicine:surgery:vascular:pathology:dvt:001",
        "title": "DVT Definition",
        "strength": 1.0
      }
    ],
    "skos:related": [
      {
        "@id": "urn:wskg:medicine:hematology:anticoagulation",
        "@type": "skos:Concept",
        "skos:prefLabel": "Anticoagulation Therapy"
      }
    ]
  },
  "pedagogical": {
    "estimated_time": "15min",
    "clinical_pearls": [
      "DOACs are first-line for most DVT - simpler, safer than warfarin",
      "Apixaban has the best bleeding safety profile among DOACs",
      "Cancer = LMWH or DOAC (NOT warfarin)",
      "Antiphospholipid syndrome = warfarin (NOT DOACs)",
      "Unprovoked DVT = extended anticoagulation, reassess risk/benefit annually"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "429221004",
      "description": "Anticoagulant therapy"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "Z79.01",
      "description": "Long term (current) use of anticoagulants"
    }
  ],
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). dvt-007-anticoagulation. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}